Volume 3.34 | Sep 4

Pulmonary Cell News 3.34 September 4, 2014
Pulmonary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PULCN on Twitter
Respiratory Transmission of an Avian H3N8 Influenza Virus Isolated from a Harbor Seal
Researchers evaluated a panel of avian H3N8 viruses and found that the harbor seal virus displays increased affinity for mammalian receptors, transmits via respiratory droplets in ferrets and replicates in human lung cells. [Nat Commun] Abstract | Press Release
Got cells? Jumpstart your research with ready to use immune and hematopoietic cells.
PUBLICATIONS (Ranked by impact factor of the journal)
Inter-Species Inference of Gene Set Enrichment in Lung Epithelial Cells from Proteomic and Large Transcriptomic Data Sets
Researchers developed an algorithm to predict differential gene set enrichment as part of the sbv IMPROVER Species Translation Challenge, which focused on phosphoproteomic and transcriptomic measurements of normal human bronchial epithelial primary cells under various stimuli and corresponding measurements in rat primary cells. [Bioinformatics] Abstract | Full Article

Linking Polymorphic p53 Response Elements with Gene Expression in Airway Epithelial Cells of Smokers and Cancer Risk
To connect p53 response element (p53RE) single-nucleotide polymorphism (SNP) genotype with gene expression and cancer risk, scientists identified a set of 204 SNPs in putative p53REs, and performed cis expression quantitative trait loci analysis, assessing associations between SNP genotypes and mRNA levels of adjacent genes in bronchial epithelial cells obtained from 44 cigarette smokers. [Hum Genet] Abstract

Altered Surfactant Homeostasis and Alveolar Epithelial Cell Stress in Amiodarone Induced Lung Fibrosis
Researchers aimed to establish a murine model of amiodarone induced lung fibrosis and analyze surfactant homeostasis, lysosomal and endoplasmic reticulum stress in this model. [Toxicol Sci] Abstract

Involvement of TLR2 and EGFR Signaling in Epithelial Expression of Airway Remodeling Factors
To elucidate the impact of Staphylococcus aureus (SA) on epithelial mediated remodeling of allergic airways, scientists tested the hypothesis that SA can enhance the remodeling process. Normal human bronchial epithelial cells were stimulated with heat killed SA or TGF-α. [Am J Respir Cell Mol Biol] Abstract


Gamabufotalin, a Bufadienolide Compound from Toad Venom, Suppresses COX-2 Expression through Targeting IKKbeta/NF-KappaB Signaling Pathway in Lung Cancer Cells
The biological functions of gamabufotalin (CS-6) were investigated by migration, colony formation and apoptosis assays in NSCLC cells. The nuclear localization and interaction between transcriptional co-activator p300 and NF-kappaB p50/p65 and their binding to COX-2 promoter were analyzed after treatment with CS-6. [Mol Cancer] Abstract | Full Article

Transforming Growth Factor-β-Induced miR-143 Expression in Regulation of Non-Small Cell Lung Cancer Cell Viability and Invasion Capacity In Vitro and In Vivo
Scientists investigated the effects of transforming growth factor-β-induced miR-143 expression in regulation of non-small cell lung cancer cell viability, invasion capacity in vitro, and xenograft formation and growth in nude mice. [Int J Oncol] Abstract

BRMS1 Regulates Apoptosis in Non-Small Cell Lung Cancer Cells
Researchers found that expression of breast cancer metastasis suppressor 1 (BRMS1) in A549 cells did not affect cell growth under normal culture conditions but sensitized cells to apoptosis induced by serum deprivation. Consistently, knockdown of endogenous BRMS1 expression in H1299 cells suppressed cell apoptosis. [Cell Biochem Biophys] Abstract

MyD88 Expression Is Associated with Paclitaxel Resistance in Lung Cancer A549 Cells
Scientists investigated the relationship between myeloid differentiation primary response gene 88 (MyD88) expression and the resistance to paclitaxel of A549 lung cancer cells. [Oncol Rep] Abstract

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
Efficacy of S-1 in Non-Small Cell Lung Cancer
S-1 is an oral fluoropyrimidine derivative, including three pharmacological compounds: tegafur, gimeracil and oteracil, in a molar ratio of 1: 0.4: 1. This review addresses the clinical evidence of S-1 in non-small cell lung cancer in various clinical settings. [Expert Opin Pharmacother] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
Teva’s Reslizumab Delivers Clinically and Statistically Significant Reduction in Asthma Exacerbations in Two Pivotal Phase III Studies
Teva Pharmaceutical Industries Ltd. announced that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma exacerbations compared to placebo in two pivotal Phase III studies in patients with inadequately controlled moderate to severe asthma with elevated levels of blood eosinophils. [Teva Pharmaceutical Industries Ltd.] Press Release

FDA Grants Fast Track Designation to Aradigm’s Pulmaquin for Non-Cystic Fibrosis Bronchiectasis
Aradigm Corporation announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to its lead product candidate, Pulmaquin®, for treatment of non-cystic fibrosis bronchiectasis patients with chronic lung infections with Pseudomonas aeruginosa. Aradigm is currently in Phase III clinical trials for this indication. [Aradigm Corporation] Press Release

Global Cancer Diagnostics Announces Start of Final Validation Study for Its New Blood Test for the Early Detection of Lung Cancer
Global Cancer Diagnostics Inc. announced the start of the final validation study of its new blood test for early detection of lung cancer. [Global Cancer Diagnostics Inc. (Business Wire)] Press Release

Mirati Therapeutics Initiates Phase I Study of MGCD516 for Non-Small Cell Lung Cancer and Other Advanced Solid Tumors
Mirati Therapeutics, Inc. announced that the first patient has been dosed in its Phase I clinical study of MGCD516 in the treatment of patients with advanced solid tumors, with an initial focus on non-small cell lung cancer. [Mirati Therapeutics, Inc.] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the
Human Immunology Portal.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Clinical Applications of Stem Cells (CASC) 2015
February 26-27, 2015
Singapore, Singapore

NEW BIT’s 8th Annual World Cancer Congress (WCC-2015)
May 15-17, 2015
Beijing, China

Visit our events page to see a complete list of events in the pulmonary cell community.
NEW Postdoctoral Research Fellow – Biology of Small Cell Lung Cancer (Fred Hutchinson Cancer Research Center)

NEW Postdoctoral Researcher – Cancer (Ohio State University)

NEW Laboratory Head – Epithelial Cancer Program (Peter MacCallum Cancer Centre)

NEW PhD or MD-PhD Student – Pediatric Respiratory Epidemiology (University of Bern)

Postdoctoral Research Trainee – Acute Lung Injury (University of Tennessee Health Science Center)

Postdoctoral Scientist – Clinical and Experimental Pharmacology Group (Cancer Research UK Manchester Institute)

Research Assistant – Lung Cancer (University of Cambridge)

Postdoctoral Fellow – Development of the Esophagus and Lung (University of Rochester Medical Center)

Scientist – Pluripotent Stem Cell Biology Endoderm Lineages (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Pulmonary Cell News: Archives | Events | Contact Us